Loading...
First Round of Abstract Submission Ends: Apr 15, 2026
Extended Early Bird Ends: Aug 28, 2025

Plenary Speakers

Prof. Guido Kroemer
Universite Paris Cite, France
Title: Neuroendocrine control of the immune response
Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris-Cité, Director of the research team "Metabolism, Cancer and Immunity" of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France.

Dr. Kroemer’s work focuses on the pathophysiological implications of cell stress and death in the context of aging, cancer and inflammation. He discovered the ignition of regulated cell death pathways by mitochondrial membrane permeabilization, the cytoprotective and antiaging effects of macroautophagy, as well as the decisive role of immunogenic cell death in anticancer treatments.

With over 1630 articles including 72 in the ‘CNS’ journals Cell (16 papers), Nature (6), Nature Medicine (24), Science (18) and Science Translational Medicine (8) and an h-index of 303, he is worldwide most cited researcher in Biology and Biochemistry (https://research.com/scientists-rankings/biology-and-biochemistry). Kroemer is the founding Editor-in-Chief of six journals: Cell Death & Disease, Cell Stress, Geromedicine, OncoImmunology, Microbial Cell, and Molecular & Cellular Oncology. He is the Editor-in-Chief of Seminars in Immunology.

Dr. Kroemer is member of the Academia Europaea, Austrian Academy of Sciences, Chinese Academy of Engineering, European Academy of Cancer Sciences (EACS), European Academy of Sciences (EAS), European Academy of Sciences and Arts (EASA), European Molecular Biology Organization (EMBO), German Academy of Sciences (Leopoldina), Institut Universitaire de France (IUF) and Royal Spanish Academy of Sciences. He is the Founding President of the European Academy of Tumor Immunology (EATI).

Dr. Kroemer’s contributions have been recognized with multiple awards including the most prestigious cancer research prizes from Belgium (Baillet-Latour Health Prize), France (Prix Duquesne, Prix Léopold Griffuel, Grand Prix Ruban Rose) and Switzerland (Brupbacher Prize), the European Union-sponsored Descartes Prize, as well as the most important Italian science prize (Lombardia & Ricerca Prize).
Prof. Jiri Mestecky
University of Alabama at Birmingham, USA
Title: Will update soon.
Will update soon.
Prof. Wolf H. Fridman
University of Paris, France
Title: Will update soon.
Professor Wolf H. Fridman is Professor Emeritus of Immunology at the Université Paris Cité, France. He received his MD and PhD degrees from the University of Paris. After 10 years in the laboratory headed by Jean Dausset, he created his own laboratory at the Cancer Research Centre in Villejuif in 1976, then moved to Institut Curie in 1983. In 2007 he created and directed the Cordeliers Research Centre. He has been President of the Canceropole Ile de France. Dr Fridman’s research interests have been focused around the role of the immune system in controlling human tumors and the biological functions of receptors for IgG antibodies,. He, and his team, identified the ITIM motif, an inhbitory motif common to many receptors. He, then, focused on the analysis of the tumor microenvironment of human cancers. Since 2005, his studies have changed the paradigm of host/cancer interactions by demonstrating that the ‘immune contexture”, taking in account the functionality, the location and the density of the immune infiltrate in colorectal tumors, is the major prognostic factor for human cancers. More recently, he, and his team, demonstrated that Tertiary Lymphoid Structures (TLS) and B cells, predict favorable clinical outcome and therapeutic response to immunotherapy in cancer patients and analyzed the mechanisms underlying these impacts. These findings open the way for novel immune-based tools for efficient prognosis and therapy of cancers.
Prof. Catherine Sautes-Fridman
Cordeliers Research Centre, Paris, France
Title: Tumor heterogeneity and immunotherapy response
Catherine Sautès-Fridman (orcid.org/0000-0003-1735-8722) is Professor Emeritus at the University Paris Cité. Former director of the “Cancer, immunology and immunopathology” department (2007- 2016) and director of the “Immunity and cancer” team (2006-2013) at CRC, she focuses her research on the heterogeneity of the immune and inflammatory components of the microenvironment tumor in human cancers to identify new prognostic and theranostic markers. She carried out work in several fields: histocompatibility antigens (demonstration of the association of HLA antigens with beta2- microglobulin and description of the 3rd histocompatibility locus, Néauport-Sautès C), receptors for IgG antibodies (biological activity and 3D structure, Sautès C and Sautès-Fridman), immuno-oncology (role of IL17, tumor microenvironment immune profiles of patients at risk of disease progression, role of Tertiary Lymphoid Structures -TLS- Sautès-Fridman C). She has trained 15 doctoral students and 18 master's students. Former French Society of Immunology and European Federation of Immunological Societies, EFIS, president she promoted immunology in Europe, the “EFIS-EJI Ita Askonas Award” to acknowledge female group leaders in immunology, and founded the first European Congress of Immunology (ECI, 5000 participants) in 2006 in Paris. Editor-in-chief of " La Revue Immunité et cancer ".
Prof. Junji Yodoi
Kyoto University, Japan
Title: 50 Yrs Update of TRX/ADF/IgEBF and Redoxisome; Basic Regulator of Allergy, Inflammation and Stress Diseases
Dr. Junji Yodoi is the Prof.Em. Kyoto University and is the Chairman of JBPA (Japan Biostress Research Promotion Alliance). He is also the Research Advisor of KITC(Kyoto Municipal Institute of Industrial Techinology and Culture)(2023-). He is the discoverer of Adult T Cell Leukemia ATL, related to HTLV retrovirus, with his mentor Dr. Kiyoshi Takatsuki and others in early 70’s. He graduated from Kyoto Univ. Med.Sch M.D. 1971 and got Ph.D. 1981 . He was Assistant Professor in the Institute for Immunology in the Medical School ( Discoverer of IgE Immunoglobulin E. Kimishige Ishizaka Dept Head, in Kyoto Univ. Joint Appointment with Johns Hopkins Baltimore.) Research Associate in Johns Hopkins University Department of Medicine under Prof. Kimishige Ishizaka (1977-1980). He was the full professor in the Inst Virus Research Kyoto University (1989-2010). He was also appointed as the Human Stress Signal Research Center, Head od BioMedical SpecialResearch Unit, AIST (National Inst Advanced Industrial Science and Technology Japan) from 2001 to 2004. He was also a group leader of Translational Res Center, Thioredoxin Project, in Kyoto Univ Hospital from 2003 to 2007. He is a core member of International Redox Network, IRN, since 2004 and editorial board member of Redox-related many Journals. He was a WCU Distiuguished Invited Prof in Ewha Womans Univ. Seoul. (2011-2013) Member of UNESCO MCBN 1998, FASEB, Society of Mucosal Immunology, Japanese Society of Immunology, Japanese Society of Cancer.
Prof. Pier Giuseppe Pelicci
Title: Cancer adaptive-phenotypes in metastasis and drug-resistance
Prof. Pier Giuseppe Pelicci is Director of Research and Chairman of the Department of Experimental Oncology of the European Institute of Oncology (IEO), in Milan. He is also full professor at the University of Milan, President of the European School of Molecular Medicine (SEMM) and Vice-President of Alliance Against Cancer (ACC), a network of 28 cancer research hospitals promoted and coordinated by the Ministry of Health, engaged in the set-up of multicentric mechanism–based clinical trials. With a medical degree, a specialty in Internal Medicine and a PhD in Molecular Biology, he devoted his life to research, in the field having major impact on today’s clinical approach of treating cancer patients, such as the identification/functional characterization of PML-RAR and mutated-NPM oncogenes and the definition of the molecular basis of the current standard targeted treatment More recently, he has been focusing on the biological and molecular characterization of normal and cancer stem cells, on the mechanisms of DNA damage, on relapse acquired chemoresistance in leukaemia, and obesity as cancer risk factor.
Florian Sennlaub
INSERM, France
Title: Will Update Soon
Florian Sennlaub, M.D., Ph.D., is Research Director at the French National Institute of Health and Medical Research (INSERM), Director of the Retinal Immunology Laboratory, and Director of the Department of Therapeutics at the Institut de la Vision, Sorbonne University, Paris.

He earned his medical degree at Ludwig Maximilians University in Munich, trained in ophthalmology at Humboldt University in Berlin, and obtained a Ph.D. in Paris on ocular neovascularization before completing postdoctoral research on oxidative stress at St. Justine’s Hospital in Montréal. He founded his own group in 2008 and joined the Institut de la Vision in 2012.

Dr. Sennlaub’s laboratory investigates the immunological mechanisms driving retinal disease, with a particular focus on age-related macular degeneration (AMD). His team has demonstrated that chronic accumulation and dysfunction of mononuclear phagocytes (MPs) are central to AMD pathology, linking persistent inflammation to photoreceptor degeneration and neovascularization. His research has further shown how genetic AMD risk variants as well as environmental factors, impair immune regulation, hinder resolution of subretinal inflammation, and accelerate disease progression. These discoveries highlight inflammation as a key driver of AMD and provide novel therapeutic avenues to limit pathogenic, non-resolving immune responses. .

Dr. Sennlaub has authored more than 130 publications, including landmark studies in Nature Medicine, JCI, and Immunity. He serves on the steering committee of the Institut de la Vision, as well as on scientific advisory boards for academic and industry partners in ophthalmology.